Related Experiment Video
Updated: Oct 20, 2025

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers
Published on: March 1, 2024
Comprehensive characterization of somatic variants associated with intronic polyadenylation in human cancers
Zhaozhao Zhao1, Qiushi Xu1, Ran Wei1,2
1State Key Laboratory of Genetic Engineering, Collaborative Innovation Center of Genetics and Development, Human Phenome Institute, School of Life Sciences and Huashan Hospital, Fudan University, Shanghai 200438, P.R. China.
Abstract:
Somatic single nucleotide variants (SNVs) in cancer genome affect gene expression through various mechanisms depending on their genomic location. While somatic SNVs near canonical splice sites have been reported to cause abnormal splicing of cancer-related genes, whether these SNVs can affect gene expression through other mechanisms remains an open question. Here, we analyzed RNA sequencing and exome data from 4,998 cancer patients covering ten cancer types and identified 152 somatic SNVs near splice sites that were associated with abnormal intronic polyadenylation (IPA). IPA-associated somatic variants favored the localization near the donor splice sites compared to the acceptor splice sites. A proportion of SNV-associated IPA events overlapped with premature cleavage and polyadenylation events triggered by U1 small nuclear ribonucleoproteins (snRNP) inhibition. GC content, intron length and polyadenylation signal were three genomic features that differentiated between SNV-associated IPA and intron retention. Notably, IPA-associated SNVs were enriched in tumor suppressor genes (TSGs), including the well-known TSGs such as PTEN and CDH1 with recurrent SNV-associated IPA events. Minigene assay confirmed that SNVs from PTEN, CDH1, VEGFA, GRHL2, CUL3 and WWC2 could lead to IPA. This work reveals that IPA acts as a novel mechanism explaining the functional consequence of somatic SNVs in human cancer.
Insights
Somatic single nucleotide variants (SNVs) near splice sites can cause abnormal intronic polyadenylation (IPA), a novel mechanism affecting gene expression in cancer. This finding impacts understanding of cancer-related gene mutations and their functional consequences.
Area of Science:
- Genomics
- Molecular Biology
- Cancer Research
Background:
- Somatic single nucleotide variants (SNVs) in cancer genomes can alter gene expression.
- While SNVs near splice sites are known to cause abnormal splicing, other mechanisms remain unexplored.
Purpose of the Study:
- To investigate novel mechanisms by which somatic SNVs affect gene expression in cancer.
- To identify and characterize SNVs associated with abnormal intronic polyadenylation (IPA).
Main Methods:
- Analysis of RNA sequencing and exome data from 4,998 cancer patients across ten cancer types.
- Identification of somatic SNVs near splice sites associated with IPA.
- Minigene assays to validate the functional impact of SNVs on IPA.
Main Results:
- 152 somatic SNVs associated with IPA were identified, predominantly near donor splice sites.
- IPA-associated SNVs were enriched in tumor suppressor genes (TSGs) like PTEN and CDH1.
- Genomic features like GC content and intron length differentiated IPA from intron retention.
Conclusions:
- Abnormal intronic polyadenylation (IPA) is a novel mechanism through which somatic SNVs impact gene expression in human cancers.
- Understanding SNV-associated IPA provides new insights into cancer development and potential therapeutic targets.
Related Concept Videos
Comparing Copy Number Variations and SNPs
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
RNA Splicing
Single Nucleotide Polymorphisms-SNPs
Cancers Originate from Somatic Mutations in a Single Cell
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Non-LTR Retrotransposons

